TMCnet News
Antibe Therapeutics Reports Q2 2016 Interim Financial and Operating Results and Appoints New CFOAntibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) filed its financial and operating results Thursday, November 26 for the fiscal quarter ended September 30, 2015. The Corporation's unaudited Q2 2016 financial statements and MD&A are available on SEDAR. Antibe's financial statements and operating results to September 30, 2015 do not include results from Citagenix, which was purchased on October 15, 2015 (see earlier press release for details of this transaction). The Citagenix purchase represents Antibe's initial entry into the regenerative medicine business. Financial and operating results for Citagenix will be reflected in Antibe's results for the quarter ended December 31, 2015. Antibe is also pleased to announce the appointment of Alain Wilson to the position of Chief Financial Officer. Alain is a management consultant with extensive experience in strategy and financial analysis in a variety of industries, including healthcare. Over the last 30 years Alain has worked with senior executives on key strategic issues both in North America and internationally. He was a Vice President and Toronto Office Head for Mercer Management Consulting (now Oliver Wyman (News - Alert)), and more recently a founding partner of Revelstoke Partners, a boutique consulting firm focused on assisting mid-market companies. Alain has also served as CFO, or ating CFO, of several private and public companies. Alain has an Honours Bachelor of Commerce degree from Queen's University and a Masters of Business Administration from IMD in Switzerland. About Antibe Therapeutics Inc. Antibe develops safer medicines for pain and inflammation. Antibe's technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe's lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. ATB-352, the second drug in Antibe's pipeline, targets the urgent global need for a safer analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com About Citagenix Inc. Citagenix is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become the largest source of knowledge and experience in the Canadian medical device industry when it comes to bone regeneration and is known as a valuable reference and resource by clinicians. Operating in Canada through its direct sales teams, and a network of distributor partnerships around the world, Citagenix is active in 15 countries. http://www.citagenix.com Important Note on Forward Looking Statements
View source version on businesswire.com: http://www.businesswire.com/news/home/20151201005389/en/ |
